Moleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research report report published on Saturday morning. The firm issued a sell rating on the stock. Separately, HC Wainwright reiterated a buy rating and issued a $3.00 price objective on shares of Moleculin Biotech in a research report on Thursday, December […]

Leave a Reply

Your email address will not be published.

Previous post Carnival Co. & (NYSE:CCL) Given New $24.00 Price Target at Barclays
Next post StockNews.com Begins Coverage on LightPath Technologies (NASDAQ:LPTH)